Aldeyra Therapeutics (ALDX): Director bought ~$129K

~$129K

Approx. value · 200K sh @ $0.6445

395K

Holds after · shares reported

Traded

Nov 11, 2026

Filed

Nov 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 6, 20265% stakeBarclays PLC reported a passive stake (13G) of 5.5%
2. Nov 11, 2026 · this disclosureInsiderDirector purchased ~$129K of ALDX shares in the open market

What came next

1. Nov 11, 2026InsiderCFO purchased ~$6.5K of ALDX shares in the open market
2. Nov 12, 20265% stakeAQR Capital Management, LLC reported a passive stake (13G) of 1.1%

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Aldeyra Therapeutics

For Aldeyra Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALDX page.

Other recent filings by Richard Douglas, Director

• SEC Form 4 at Aldeyra Therapeutics (ALDX)Mar 20, 2026
• SEC Form 4 at Maxcyte (MXCT)Aug 13, 2025

The full history of Richard Douglas, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Aldeyra Therapeutics

• SEC Form 4Nov 13, 2026
• SEC Schedule 13GNov 12, 2026
• SEC Schedule 13GNov 6, 2026
• SEC Form 4Jun 5, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 4Mar 20, 2026

Everything OQRO holds on this company is on its ALDX page.